High XIST and Low 53BP1 Expression Predict Poor Outcome After High-Dose Alkylating Chemotherapy in Patients With a BRCA1-like Breast Cancer

Molecular Cancer Therapeutics - United States
doi 10.1158/1535-7163.mct-15-0470
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Early Stage Cost-Effectiveness Analysis of a Brca1-Like Test to Detect Triple Negative Breast Cancers Responsive to High Dose Alkylating Chemotherapy

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

High-Dose Chemotherapy in High-Risk Breast Cancer

Breast Cancer Research
Cancer ResearchOncology
2000English

Low Expression of TFPI-2 Associated With Poor Survival Outcome in Patients With Breast Cancer

BMC Cancer
Cancer ResearchOncologyGenetics
2013English

High-Dose Chemotherapy (CTM) for Breast Cancer

Bone Marrow Transplantation
TransplantationHematology
2000English

The Feasibility of High-Dose Chemotherapy in Breast Cancer Patients With Impaired Left Ventricular Function

Bone Marrow Transplantation
TransplantationHematology
2000English

Fatigue and Relating Factors in High-Risk Breast Cancer Patients Treated With Adjuvant Standard or High-Dose Chemotherapy: A Longitudinal Study

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2005English

Is High-Dose Chemotherapy With Autologous Hematopoietic Stem Cell Transplantation in Breast Cancer Patients a Done Deal?

Women's Health
Medicine
2010English

High-Dose Chemotherapy and Haematopoietic Stem Cell Transplantation for Inflammatory Breast Cancer: Pathologic Response and Outcome

Bone Marrow Transplantation
TransplantationHematology
1998English

High Cyclin B1 Expression Is Associated With Poor Survival in Breast Cancer

British Journal of Cancer
Cancer ResearchOncology
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy